Breakdown | |||||
TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|
Income Statement | Total Revenue | ||||
8.60B | 8.56B | 7.36B | 5.52B | 5.20B | 4.88B | Gross Profit |
3.23B | 3.21B | 2.72B | 2.08B | 1.98B | 1.83B | EBIT |
1.05B | 1.07B | 652.00M | 622.00M | 585.00M | 495.00M | EBITDA |
1.75B | 1.63B | 1.15B | 755.00M | 853.00M | 736.00M | Net Income Common Stockholders |
906.00M | 890.00M | 609.00M | 355.00M | 427.00M | 254.00M |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
1.12B | 1.12B | 1.02B | 944.00M | 1.35B | 1.88B | Total Assets |
16.50B | 16.50B | 16.11B | 7.95B | 8.28B | 8.75B | Total Debt |
2.02B | 2.02B | 2.39B | 1.95B | 2.44B | 3.08B | Net Debt |
895.00M | 895.00M | 1.37B | 1.00B | 1.09B | 1.21B | Total Liabilities |
5.62B | 5.62B | 5.94B | 4.45B | 5.05B | 5.77B | Stockholders Equity |
10.64B | 10.64B | 10.17B | 3.49B | 3.22B | 2.97B |
Cash Flow | Free Cash Flow | ||||
889.00M | 942.00M | 566.00M | 388.00M | 330.00M | 641.00M | Operating Cash Flow |
1.21B | 1.26B | 837.00M | 596.00M | 538.00M | 824.00M | Investing Cash Flow |
-446.00M | -482.00M | -628.00M | -191.00M | -183.00M | -169.00M | Financing Cash Flow |
-649.00M | -615.00M | -157.00M | -790.00M | -855.00M | 473.00M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
79 Outperform | $8.03B | 27.54 | 17.61% | 0.86% | 3.89% | 8.17% | |
78 Outperform | $16.08B | 25.21 | 18.59% | 1.04% | -0.42% | 3.23% | |
77 Outperform | $506.37M | 41.69 | 10.86% | ― | 11.22% | 229.35% | |
73 Outperform | $3.67B | 25.59 | 17.68% | 1.14% | 10.96% | 43.44% | |
72 Outperform | $30.51B | 33.73 | 8.62% | 1.28% | 8.14% | 32.64% | |
72 Outperform | $6.07B | 21.76 | 14.00% | 1.81% | 4.23% | 20.40% | |
63 Neutral | $769.73M | 8.52 | 4.79% | 3.74% | 1.11% | -32.34% |
On May 13, 2025, Xylem Inc. held its Annual Meeting of Shareholders, where 88.68% of the company’s outstanding common stock was represented. Key outcomes included the election of nine directors, ratification of Deloitte & Touche LLP as the independent auditor for 2025, approval of executive compensation, and the rejection of a shareholder proposal for special shareholder meeting improvements.
The most recent analyst rating on (XYL) stock is a Buy with a $148.00 price target. To see the full list of analyst forecasts on Xylem stock, see the XYL Stock Forecast page.